Article citationsMore>>

Xiang, Y., Fang, B., Liu, Y., Yan, S., Cao, D., Mei, H., Wang, Q., Hu, Y. and Guo, T. (2020) SR18292 Exerts Potent Antitumor Effects in Multiple Myeloma via Inhibition of Oxidative Phosphorylation. Life Sciences, 256, Article ID: 117971.
https://doi.org/10.1016/j.lfs.2020.117971

has been cited by the following article:

• TITLE: PLAGL1 Is Identified as a Potential Diagnostic Marker for Co-Occurrence with Osteoporosis and Multiple Myeloma

  AUTHORS: Wencong Zhang, Jiani Mo, Aiguo Li

  KEYWORDS: Osteoporosis, Multiple Myeloma, PLAGL1, Immunity, Weighted Gene Co-Expression Network Analysis

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 26, 2023

  ABSTRACT: Background: Osteoporosis (OP) is a common clinical manifestation of multiple myeloma (MM). The aim of this study was to investigate the possible molecular pathways and shared genes in the co-occurrence of OP and MM. Methods: The Gene Expression Omnibus database was used to retrieve gene expression information. Use WGCNA and differential analysis to screen out Hub genes. The GENEMANIA was used to build protein-protein interaction (PPI) networks. Enrichment analyses were performed to explore the functions. Validation datasets were selected to verify the diagnostic marker reliability of PLAGL1. The immune microenvironment of diseases was analyzed by immune infiltration analyses. Results: We confirmed a hub gene called PLAGL1, which is significantly under-expressed in both OP and MM. We found hub genes were associated with glucose and energy metabolism. Subsequently, the reliability of PLAGL1 for diagnosing OP and MM was verified using ROC curves, with all areas under the curve > 0.75. Moreover, PLAGL1 regulates t lymphocytes and may participate in the occurrence of OP in MM through immune pathways. Conclusions: PLAGL1 is a hub gene for the co-occurrence of OP and MM. It can regulate T-lymphocyte involvement in disease development. PLAGL1 may be a novel diagnostic marker for the co-occurrence of OP and MM.